AGAMREE (vamorolone)

Self-Administration – oral

Diagnosis considered for coverage:
  • DMD: Indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older
Coverage Criteria:

For diagnosis of Duchenne muscular dystrophy (DMD):

  • Diagnosis of Duchenne muscular dystrophy (DMD), AND
  • Patient is 2 years of age or older, AND
  • Patient has received genetic testing for a mutation of the dystrophin gene, AND
  • One of the following:
    • Patient has a confirmed mutation of the dystrophin gene, OR
    • Muscle biopsy confirmed an absence of dystrophin protein, AND
  • Patient has had a trial and failure or intolerance to prednisone or prednisolone given at a dose of 0.75 mg/kg/day or 10 mg/kg/weekend, AND
  • Prescribed by or in consultation with a neurologist who has experience treating children, AND
  • One of the following:
    • For patients less than or equal to 50kg, dose will not exceed 6mg/kg of body weight once daily, OR
    • For patients greater than 50kg, dose will not exceed 300mg/day
Reauthorization Criteria:

For diagnosis of Duchenne muscular dystrophy (DMD):

  • Patient has experienced a benefit from therapy (e.g., improvement in preservation of muscle strength), AND
  • One of the following:
    • For patients less than or equal to 50kg, dose will not exceed 6mg/kg of body weight once daily, OR
    • For patients greater than 50kg, dose will not exceed 300mg/day, AND
  • Patient has had a trial and failure or intolerance to prednisone or prednisolone given at a dose of 0.75 mg/kg/day or 10 mg/kg/weekend
Coverage Duration:
  • Initial: 1 year
  • Reauthorization: 1 year
Dosing:

For diagnosis of Duchenne muscular dystrophy (DMD):

  • Recommended dose: 6 mg/kg taken orally once daily
  • Maximum dose: 300 mg daily for patients weighing more than 50 kg
  • Some patients may respond to a dose of 2 mg/kg daily. Doses may be titrated down to 2 mg/kg/day as needed, based on individual tolerability
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information:
  • Approximately 70% of individuals with DMD have a single-exon or multi-exon deletion or duplication in the dystrophin gene, dystrophin gene deletion, and duplication testing is usually the first confirmatory test. If genetic testing does not confirm a clinical diagnosis of DMD, then a muscle biopsy sample should be tested for the presence of dystrophin protein by immunohistochemistry of tissue cryosections or by western blot of a muscle protein extract.
  • Prednisone 0.75 mg/kg/d should be considered the optimal prednisone dose in DMD. Over 12 months, prednisone 10 mg/kg/weekend is equally effective, although long term outcomes of this alternative regimens are unknown.
Policy Updates:
  • 9/1/2024 (policy effective date) – New policy approved by WHA P&T Committee. (P&T, 8/20/2024) (P&T meeting date) 
References:
  1. Agamree Prescribing Information. Catalyst Pharmaceuticals, Inc. Coral Gables, FL. October 2023
  2. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. The Lancet Neurology. 2018;17(3):251-267.
  3. Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465-72.

Last review date: September 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone